Firebrick Pharma (ASX:FRE)
ASX announcement history & article coverage
Transparent by design.
Announcments by Firebrick Pharma (ASX:FRE) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Nasodine Nasal Spray Approved in the Philippines
Firebrick Pharma secures Philippine OTC approval for Nasodine Nasal Spray
Notice of AGM & Proxy Form & Letter to Shareholders
Proposed issue of securities - FRE
Firebrick Secures $732k in Strategic Investments
Firebrick Pharma raises $732,000 with Philippines partner increasing stake above 10%
Firebrick Investor Update Presentation
Firebrick announces USA Retail Launch Plan
Firebrick approves phased US retail pharmacy launch for Nasodine
Firebrick receives $293,000 R&D Tax Incentive
Firebrick Pharma receives $293,000 R&D tax incentive payment
Notice of AGM and Closing Date for Director Nominations
Appendix 4G
Corporate Governance Statement
Appendix 4E and Annual Report 30 June 2026
Firebrick Pharma reports $3.06 million loss with early Nasodine commercialisation progress and $3.17 million capital raised
Cleansing Notice
Application for quotation of securities - FRE
Proposed issue of securities - FRE
Update - Notification regarding unquoted securities - FRE
Investor Update
Firebrick Pharma advances Nasodine commercialisation with US sales growth and Southeast Asia expansion
June 2026 Quarterly Activity Report
Firebrick Pharma reports patent grants, 43% sales growth, and stable cash burn in June 2026 quarter